VPA is metabolised in the mitochondria to valproyl-coenzyme A, which inhibits N-acetylglutamate synthase, thereby limiting detoxification of ammonia to carbamoyl phosphate and also resulting in secondary carnitine deficiency [19]. The gene discussed is NAGS; the disease is systemic primary carnitine deficiency disease.